Antiplatelet and antithrombotic effect of F 16618, a new thrombin proteinase‐activated receptor‐1 (PAR1) antagonist

Abstract

F 16618 was shown to have strong antithrombotic activity in vivo and moderate antiplatelet effects ex vivo. As these effects were not associated with major effects on physiological haemostasis, this molecule is a good antiplatelet drug candidate for use either alone or in combination with current treatments.